The Janssen and AbbVie (NYSE: ABBV) partnered drug Imbruvica (ibrutinib) has now nabbed five European Commission (EC) approvals in as many years, as its use was broadened in two indications.
Firstly, it can now be used in combination with Roche’s (ROG: SIX) Gazyvaro (obinutuzumab) in previously untreated chronic lymphocytic leukemia (CLL), based on Phase III data from the iLLUMINATE study.
Also, it can now be prescribed with Rituxan, a drug first marketed by Roche as Rituxan/MabThera, to treat Waldenström's macroglobulinemia (WM), this time based on Phase III iNNOVATE data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze